Amedisys Inc

Amedisys — Q1 2025 Earnings Presentation

11 slides from Amedisys's earnings presentation, Apr 23, 2025

  1. Slide 1: Amedisys First Quarter 2025 Earnings Release Supplemental Slides

    1 Amedisys First Quarter 2025 Earnings Release Supplemental Slides April 23, 2025 EXHBIT 99.2

  2. Slide 2: Forward-Looking Statements

    2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c

  3. Slide 3: Highlights and Summary Financial Results (Adjusted): 1Q'25

    3 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 1Q’25(1) 1. The financial results for the three-month periods ended March 31, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included i

  4. Slide 4: Revenue Mix and Reimbursement by Payor

    4 55.7% 17.6% 26.7% Home Health Revenue Medicare FFS Private Episodic & Case Rate Per Visit 63.8% 34.6% 1.6% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30

  5. Slide 5: Home Health and Hospice Segment (Adjusted) – 1Q'25

    5 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – 1Q’25(1) • Medicare revenue per episode up 0.3% primarily due to the 0.5% rate increase effective 1/1/2025. • Y/Y Total CPV up $3.35 (+2.9%) primarily due to raises, wage inflation and an increase in salaried clinicians and clinical managers. • EBITDA m

  6. Slide 6: General & Administrative Expenses – Adjusted

    6 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 80 basis points • $2.8 million increase in total G&A is primarily due to planned wage increases, employee-related insurance costs and higher information technology fees partial

  7. Slide 7: Industry Leading Quality Scores

    7 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jan 2025 HHC Final release with 88% of our providers (representing 88% of care centers) at 4+ Stars and 46% of our providers (representing 42% of care centers) at 4.

  8. Slide 8: Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class

    8 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. CMS Nat is an average of all providers nationally, excluding active AMED providers. EXHBIT 99.2

  9. Slide 9: Debt and Liquidity Metrics

    9 DEBT AND LIQUIDITY METRICS Net leverage ~0.3x 1. Net debt defined as total debt outstanding ($371.8M) less cash and cash equivalents ($284.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($254.7M). 3. Liquidity defined as the sum of cash balance an

  10. Slide 10: Cash Flow Statement Highlights

    10 CASH FLOW STATEMENT HIGHLIGHTS (1) 1Q’25 operating cash flow impacted by the timing of the payment of accounts payable and accrued expenses and a buildup in accounts receivable which is typical in the first quarter. 1. Free cash flow defined as cash flow from operations less routine capital expen

  11. Slide 11: Income Statement Adjustments

    11 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 have been adjusted for the certain items above. A reconciliation of our non-GAAP financial measures, which include th

Amedisys — Q1 2025 Earnings Presentation on 6ix